(TOCA) –
-
Tocagen Announces Change to Virtual Format for Special Meeting of Stockholders
-
Tocagen Reports First Quarter 2020 Financial Results
-
Tocagen Reports Fourth Quarter and Full Year 2019 Financial Results
-
Tocagen and Forte Biosciences Announce Merger
-
Tocagen (TOCA) Toca 5 Phase 3 Trial Results Presented at SNO
-
Toca 5 Phase 3 Trial Results Presented at the Society for Neuro-Oncology Annual Meeting
-
Tocagen Reports Third Quarter 2019 Financial Results and Business Updates
-
Tocagen (TOCA) Announces Data from Toca 6 Phase 1b Study of Toca 511 and Toca FC in Patients with Non-CNS Tumors
-
Tocagen Highlights Toca 6 Phase 1b Data at Society for Immunotherapy of Cancer Annual Meeting
-
Tocagen to Report Third Quarter 2019 Financial Results and Business Updates on Tuesday, November 12
-
Tocagen (TOCA) Announces Restructuring to Focus on Clinical Development
-
Tocagen Announces Restructuring to Focus on Clinical Development
-
Tocagen Inc. (TOCA) PT Lowered to $1 at SVB Leerink
-
Chardan Capital Markets Downgrades Tocagen Inc. (TOCA) to Neutral
-
Citi Downgrades Tocagen Inc. (TOCA) to Neutral
-
B.Riley/FBR Downgrades Tocagen Inc. (TOCA) to Neutral
-
Ladenburg Thalmann Downgrades Tocagen Inc. (TOCA) to Neutral
-
Evercore ISI Downgrades Tocagen Inc. (TOCA) to In Line
-
H.C. Wainwright Downgrades Tocagen Inc. (TOCA) to Neutral
-
Cantor Fitzgerald Downgrades Tocagen Inc. (TOCA) to Neutral
-
Increasing unusual option volume: VIAV HRL TOCA
-
Baird Downgrades Tocagen Inc. (TOCA) to Neutral
-
Pre-Open 09/12: (RVG) (LKQ) (RNG) Higher (TOCA) (ADVM) (TLRD) Lower (more...)
-
Wall Street ends higher on trade, ECB stimulus hopes
-
Tocagen (TOCA) Plunges 65% After Toca 5 Phase 3 Trial in Recurrent Brain Cancer Fails
-
Tocagen (TOCA) Highlights Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer
-
Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer
-
Tocagen to Participate in Two Upcoming Investor Conferences
-
Tocagen (TOCA) Tops Q2 EPS by 4c
-
Tocagen Reports Second Quarter 2019 Financial Results and Business Updates
-
Tocagen to Report Second Quarter 2019 Financial Results and Business Updates on Thursday, August 8
-
Tocagen to Present at Upcoming Jefferies 2019 Healthcare Conference
-
Citi Assumes Tocagen Inc. (TOCA) at Buy
-
Pre-Open Movers 05/22: (CLNE) (AVP) (TGT) Higher; (EKSO) (TOCA) (AMBA) (more...)
-
Tocagen Inc. (TOCA) PT Lowered to $10 at Chardan Capital Markets
-
Tocagen Inc. (TOCA) PT Lowered to $16 at Ladenburg Thalmann
-
Tocagen Inc. (TOCA) PT Lowered to $5 at SVB Leerink
-
After-Hours Movers 05/21: (PVH) (LGF-A) Higher; (TOCA) (EKSO) (LIQT) (more...)
-
Tocagen (TOCA) Says Toca 5 Pivotal Phase 3 Clinical Trial in Patients with Recurrent Brain Cancer Continues Without Modification at Planned Interim Analysis
-
Tocagen's Toca 5 Pivotal Phase 3 Clinical Trial in Patients with Recurrent Brain Cancer Continues Without Modification at Planned Interim Analysis
-
Tocagen (TOCA) Tops Q1 EPS by 27c
-
Tocagen Reports First Quarter 2019 Financial and Business Results
-
Tocagen to Report First Quarter 2019 Financial and Business Results on Tuesday, May 7
-
Pre-Open Stock Movers 04/26: (PETX) (MAT) (PRO) Higher; (BGG) (ATEN) (INTC) Lower (more...)
-
After-Hours Movers 04/25: (MAT) (EHTH) (PRO) Higher; (ATEN) (INTC) (BEAT) (more...)
-
Cantor Fitzgerald Starts Tocagen Inc. (TOCA) at Overweight
-
Tocagen Appoints Fairooz Kabbinavar, M.D., FACP, as Senior Vice President, Clinical Development
-
SVB Leerink Starts Tocagen Inc. (TOCA) at Market Perform
-
NetworkNewsAudio – Genprex Inc. (NASDAQ: GNPX) Establishing Itself as a Trailblazer in Breakthrough Cancer Treatments
-
Tocagen to Present Updated Data from Clinical and Preclinical Studies at Two Scientific Conferences
Back to TOCA Stock Lookup